{
  "docId": "019de077-691b-72c2-80d2-a28de652ce70",
  "docSlug": "7b833127c4e1241e21c155446b1ba76b",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 42,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes study timeline, randomization details, entry criteria, and secondary endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/26",
  "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
  "deckJsonHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70.json",
  "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.09,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study timeline showing screening, dosing, and follow-up weeks",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fba8aa5-5bfa-49a4-9252-c2df55b08fca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.66,
        "y": 0.395
      },
      "kind": "list",
      "text": "Key Entry Criteria: Men and Women, Ages 18-74, Diagnosis of MDD, MADRS >= 26",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15771ffd-2cc0-47b1-b5ae-759654e86fbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.66,
        "y": 0.6
      },
      "kind": "list",
      "text": "Secondary Endpoints: MADRS at Week 12, MADRS at Week 1, CGI-S at Day 2, Time to retreatment / inefficacy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d907885d-51ed-4fc5-816a-abb5600f330e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.17,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Study MM120-310 study documents. Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical protocols.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42a835c2-2a5a-4bd3-9f05-1b6d2121646c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.42,
        "x": 0.038,
        "y": 0.048
      },
      "kind": "title",
      "text": "Phase 3 MDD Trial Schematic: Emerge Study",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30bd72d5-2bca-40b4-b748-69fe03502df4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "010d6518-3fd7-4936-8cbf-d37806228092",
      "evidence": "Visual timeline of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 16,
      "beatId": "c93e54c1-7fba-4f94-ae19-b53dc410f312",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section spans multiple pages, showcasing the results of clinical trials and the potential of MM120.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
      "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
      "position": 1,
      "objective": "Presenting the company's vision and approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}